RxDoctor Payments DataLook up a doctor →

Alexandra Glenn

Acute Care · Birmingham, ALNPI 1275094088

Payments from drug & device makers

$10,707in general payments, 2019–2025

Across 532 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$861
  • Novartis$815
  • Johnson & Johnson$786
  • Takeda Pharmaceuticals U.S.A., Inc.$628
  • AstraZeneca$592
  • Incyte Corporation$592
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$10,51298%
  • Education$1952%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer47$861
Novartis47$815
Johnson & Johnson32$786
Takeda Pharmaceuticals U.S.A., Inc.29$628
AstraZeneca(2 entities)29$592
Incyte Corporation25$592
Lilly USA, LLC25$422
E.r. Squibb & Sons, L.L.C.22$372
Bristol Myers Squibb20$363
GSK19$330
Blueprint Medicines Corporation11$296
Regeneron Healthcare Solutions, Inc.13$258
Deciphera Pharmaceuticals Inc.13$257
Eisai Inc.15$252
Boehringer Ingelheim8$212
Bayer10$211
Genentech USA, Inc.8$188
Sobi, Inc9$185
AbbVie10$183
Seagen Inc.10$181
Servier Pharmaceuticals LLC9$177
Sumitomo Pharma America, Inc.7$151
Jazz Pharmaceuticals Inc.7$146
Pharmacosmos Therapeutics Inc.6$132
Stemline Therapeutics Inc.6$132
Amgen2$130
CSL Behring4$117
Puma Biotechnology, Inc.6$117
Beone Medicines USA, Inc.6$114
Sanofi4$102
Daiichi Sankyo Inc.5$102
Exelixis Inc.5$99
Pharmacyclics LLC, An Abbvie Company6$97
Beigene USA, Inc.5$92
Morphosys, US Inc.5$90
Spectrum Pharmaceuticals Inc.4$88
Pharmaessentia USA Corporation4$81
Ipsen Biopharmaceuticals, Inc3$65
Shield Therapeutics Inc3$55
Agios Pharmaceuticals, Inc.3$53
Merck2$45
Kyowa Kirin, Inc.2$45
Karyopharm Therapeutics Inc.2$43
Acrotech Biopharma Inc.2$40
Recordati_rare_diseases_inc.2$40
EMD Serono, Inc.2$37
Global Blood Therapeutics, Inc.2$34
Progenics Pharmaceuticals, Inc.2$32
Rigel Pharmaceuticals, Inc.2$30
Geron Corporation1$26
Gilead1$25
Azurity Pharmaceuticals, Inc.1$24
Astellas Pharma US Inc1$22
Coherus Oncology, Inc.1$21
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$20
Taiho Oncology, Inc.1$19
ADC Therapeutics America, Inc.1$19
Genmab U.S., Inc.1$16
Apellis Pharmaceuticals, Inc.1$15
Array Biopharma Inc1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,707 in reported general payments places this provider in the 95th percentile of 711 acute care providers in Alabama.

See all acute care providers in Alabama

Medicare billing

Part B allowed, 2024
$2,208
Medicare patients
28
Services billed
28

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other acute care in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →